Dimetrio is a sex hormone and a drug used for genital pathology. Progestogens. Indications for use - treatment of endometriosis.
Warehouse
1 film-coated tablet contains:
dienogest 2 mg; excipients: lactose monohydrate, corn starch, povidone (K-30), sodium starch glycolate (type A), magnesium stearate, purified water; film coating: hypromellose (E 464), hydroxypropylcellulose (E 463), talc (E 553b), hydrogenated cottonseed oil, titanium dioxide (E 171), purified water.
Contraindication
Dimetrio should not be used if any of the following conditions or diseases are present. If any of these conditions or diseases appear for the first time while using Dimetrio, the drug should be discontinued immediately.
Active venous thromboembolism; current or history of arterial or cardiovascular disease (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease); diabetes mellitus with vascular involvement.
Method of application
Take 1 tablet daily without a break in taking the drug at about the same time, with a small amount of liquid. The tablets can be taken regardless of meals.
The tablets should be taken regularly, regardless of menstrual bleeding. As soon as the tablets from one package are finished, start taking the tablets from the next package without taking a break in taking the medicine.
There is no experience of treating patients with endometriosis with Dimetrio for longer than 15 months.
You can start taking the drug on any day of the menstrual cycle.
Any hormonal contraceptives should be discontinued before starting treatment with Dimetrio. If contraception is necessary, a non-hormonal method of contraception (e.g., a barrier method) should be used in addition.
Application features
Since Dimetrio is a progestogen-only preparation, it is considered that the special warnings and precautions for the use of progestogen-containing preparations also apply to Dimetrio, although not all warnings and precautions are based on the relevant results of clinical studies with this particular preparation.
If any of the conditions/risk factors listed below worsen or first appear, an individual risk/benefit analysis should be performed before initiating or continuing Dimetrio.
Heavy uterine bleeding
Uterine bleeding, for example in women with uterine adenomyosis or uterine leiomyoma, may increase with the use of Dimetrio. If the bleeding is severe and does not stop for a long time, it may lead to anemia (in some cases - severe). In this case, it is necessary to consider stopping the drug.
Pregnant women
Dimetrio is not recommended for use in pregnant women because there is no need to treat endometriosis during pregnancy.
Children
Dimetrio is not indicated for use in children before menarche.
Drivers
No effects on the ability to drive and use machines were observed in patients taking drugs containing dienogest.
Overdose
Acute toxicity studies conducted with dienogest did not indicate a risk of acute adverse reactions in case of unintentional administration of several daily therapeutic doses. No specific antidotes exist. The use of 20-30 mg of dienogest per day (which is 10-15 times higher than the dose in a Dimetrio tablet) for more than 24 weeks was very well tolerated.
Side effects
Metabolism and metabolic disorders: weight gain, weight loss, increased appetite.
Mental disorders: depressed mood, sleep disturbances, nervousness, decreased libido, mood swings, anxiety, depression, mood lability.
From the nervous system: headache, migraine, impaired autonomic regulation, impaired attention.
From the organs of vision: dry eyes.
Storage conditions
There are no special storage requirements.
